Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression ...

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert ...

A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast ...

Extensive-stage (stage IV) SCLC, on the other hand, is a disease that has spread outside the bounds of 1 radiation field, and ...

As biomarkers continue to be explored in resectable melanoma, oncology nurses will play a crucial role in the clinical trial ...

The FDA granted a priority review to acalabrutinib for the treatment of previously untreated adults with mantle cell lymphoma ...

Oral drugs in the HR-positive, HER2-negative metastatic breast cancer space put a focus on clear patient-provider ...

An expert explained the role oncology nurses and advanced practice providers play in caring for patients with sarcoma during treatment.

Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma. A nurse practitioner discusses her role in caring for ...

Inavolisib plus palbociclib and fulvestrant was approved for the treatment of PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer. The FDA approved inavolisib ...